A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

Active:	No
Cancer Type:	Breast Cancer	NCT ID:	NCT03901469
Trial Phases:	Phase II	Protocol IDs:	ZEN003694-004 (primary) NCI-2019-05264 2018-003906-26
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Zenith Epigenetics
NCI Full Details:	http://clinicaltrials.gov/show/NCT03901469

Summary

This is a two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination
with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part
1 is a dose escalation and Part 2 is a Simon 2-Stage design. There are 3 expansion
cohorts: Expansion Cohort A (combination treatment in post-TROP2-ADC patients), Expansion
Cohort B (ZEN003694 monotherapy), and Expansion Cohort C (combination treatment in
TROP2-ADC-naive patients).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.